Modality
Multispecific
MOA
WEE1i
Target
CD38
Pathway
Tau
FabryProstate CaPV
Development Pipeline
Preclinical
~Aug 2017
→ ~Nov 2018
Phase 1
Feb 2019
→ Sep 2031
Phase 1Current
NCT05842945
1,844 pts·Prostate Ca
2019-02→2031-09·Recruiting
1,844 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-09-125.5y awayPh2 Data· Prostate Ca
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Recruit…
Catalysts
Ph2 Data
2031-09-12 · 5.5y away
Prostate Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05842945 | Phase 1/2 | Prostate Ca | Recruiting | 1844 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 |